Niclosamide, an inhibitor of S100A4, which inhibit colorectal cancer (CRC) progression, has entered phase II clinical trials for the treatment of metastatic CRC.[66, 67] Based on our findings, anti‐S100A5 therapy might have the ability to turn “cold” tumors into “hot” tumors and show higher effectiveness in combination with ICIs. This evidence concerns the gene S100A5 and colorectal cancer.